MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas.

Bio-Techne will feature its cell and gene therapy workflow reproducibility and scalability solutions, including its portfolio of high-quality reagents and analytical technologies, at booth 517. Highlights include the recently launched ProPak liquid GMP cytokines, which combine with Wilson Wolf's G-Rex® bioreactor, available through ScaleReady, or similar platforms to enable a closed process solution to streamline and de-risk cytokine delivery for T cell manufacturing. The booth will also showcase the Ella™ automated ELISA platform and its Simple Plex™ assays, which represent the ideal solution for QC release testing, as well as Bio-Techne's full suite of protein analytical instruments for in-process and final product characterization of cell and gene therapies.

ST. PAUL, Minn., Jan. 8, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant.  The G-Rex Grant will integrate state-of-the-art advancements into Seattle Children's Therapeutics' G-Rex based CAR-T cell platform.

"This technology has been a core component of our CAR-T platform for many years, and we have manufactured cell therapy products for hundreds of clinical trial participants using G-Rex bioreactors," said Christopher Brown, Director of GMP Manufacturing at Seattle Children's Therapeutics.

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies.  

MINNEAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS System from Waters) to deliver innovative solutions that optimize workflows, improve precision, and accelerate development timelines.

ST. PAUL, Minn., Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors.

"We are grateful to receive a G-Rex Grant to support the advancement of our lead CAR T asset into the clinic in a platform that is cost effective and scalable. This mechanism is a creative solution that provides access to expertise and a highly efficient manufacturing platform to biotechnology companies in a way that saves significant time and money," said Dr. Jordan Jarjour, Chief Scientific Officer at Moonlight Bio.

MINNEAPOLIS, Dec. 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey.

Founded in the late 2000s, MedSanTek is a leading in vitro diagnostics and research products distributor, serving Turkey and Azerbaijan. Partnering with global brands, the company provides high-quality solutions in molecular biology, immunology, cancer research, cell therapy, and more, earning a reputation for innovation and customer satisfaction in advancing science and healthcare. 

Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) metastatic breast cancer. The research-use-only assay, which consists of a qPCR detection kit as well as an isolation kit for cell-free DNA and exosomal RNA, will be featured in the Asuragen booth (#1429) at the San Antonio Breast Cancer Symposium beginning on December 10th.

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

WEST SACRAMENTO, Calif., Nov. 25, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH).

MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.

Founded in 2020, Leader Life Sciences is a scientific solutions provider dedicated to empowering the research and diagnostic community in the Middle East and North Africa (MENA) region. Serving as a catalyst for innovation, they collaborate with private and public research centers, educational institutions, and healthcare facilities to bring scientific visions to life. Their expertise spans a wide range of domains, including lab automation, digital pathology, turnkey laboratory projects and diagnostics, and beyond. Under this agreement, Leader Life Sciences will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, immunoassay kits, enzymes, small molecules, proteomic analysis instruments, and spatial biology tools to biopharma companies, laboratories, hospitals, and universities in the GCC region.

MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease.

Customers will present data from their use of novel assays and kits; company will host educational workshops and discussions for attendees

MINNEAPOLIS, Nov. 14, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its lineup of presentations and activities for the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, taking place November 19-23 in Vancouver, British Columbia. Asuragen, a Bio-Techne brand, will be exhibiting and showcasing its latest research products for breast cancer monitoring and carrier screening in booth #811.

R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation

This press release updates the IVDR Classification to Class B from the prior Class C. 

MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices.

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation

MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices.

MINNEAPOLIS, Nov. 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

UBS Global Healthcare ConferenceNovember 12, 20249:30 AM PST

Stifel 2024 Healthcare ConferenceNovember 19, 20248:00 AM EST

Stephens NASH 2024 ConferenceNovember 20, 202411:00 AM CST

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

ST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation and CellReady, has awarded G-Rex Grants totaling $475,000 to three leading investigators at the Baylor College of Medicine's (BCM) Center for Cell and Gene Therapy Institute (CAGT).

Dr. Ann Leen, a Professor in the Department of Pediatrics at BCM's CAGT, received a $275,000 G-Rex Grant for process development and IND enabling studies related to tumor-associated neoantigen specific T cell therapies for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in pre- and post-hematopoietic stem cell (HSC) transplant.  Dr. Leen has been with BCM's CAGT since 2002, is the senior or co-author on more than 100 publications, is a named inventor on 14 published patents (including several relating to G-Rex), served as the principal investigator on more than 15 clinical trials using "first in human" cell therapies, and is a co-founder of two T cell therapy companies (Allovir and Marker Therapeutics).

MINNEAPOLIS, Nov. 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy development at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.

Bio-Techne's spatial biology brands, Advanced Cell Diagnostics (ACD) and Lunaphore, are revolutionizing spatial biology research with their pioneering innovations that are advancing the development of tailored immunotherapies to improve patient outcomes.

MINNEAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the release of clinically relevant spatial biology data. The data was generated using Bio-Techne's Lunaphore branded end-to-end spatial biology offering, including its complete range of instruments (COMET) and kits that offer high-value solutions for the translational research community.

COMET, a best-in-class spatial biology platform, seamlessly integrates into standard clinical research workflows. Using off-the-shelf, clinically IHC-validated antibodies, new panels can be quickly developed and validated. Additionally, COMET enables high-plex workflow automation, adding unique value to clinical studies by facilitating robust and timely decision-making in treatment strategies.

MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2024. The quarterly dividend will be  payable November 22, 2024, to all common shareholders of record on November 11, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­ techne.com.